<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896983</url>
  </required_header>
  <id_info>
    <org_study_id>#7528289</org_study_id>
    <secondary_id>#7528289 COVID-19 CoV2Soul.RS</secondary_id>
    <nct_id>NCT04896983</nct_id>
  </id_info>
  <brief_title>National Survey of Mental Health After COVID-19 Outbreak</brief_title>
  <acronym>CoV2SoulRS</acronym>
  <official_title>National Survey of Mental Health in the Second Year After COVID-19 Outbreak: Multilevel Analysis of Individual and Societal Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Belgrade</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Novi Sad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Belgrade</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Serbian national survey - acronym CoV2Soul.RS - has been launched to document mental&#xD;
      health (MH) status and understand needs of the population in relation to the prolonged global&#xD;
      public health crisis.&#xD;
&#xD;
      This cross-sectional study will collect a representative national sample (18-65 years) by&#xD;
      multi-stage probabilistic household sampling method. Trained staff will conduct face-to-face&#xD;
      diagnostic interviews (M.I.N.I.). Battery of self-report instruments will be used to measure&#xD;
      quality of Life (QoL), level of distress, and associated protective and harmful psychological&#xD;
      and societal factors. The investigators aim to assess prevalence rates of MH disorders and&#xD;
      associated QoL in the nationally representative sample, to explore how MH conditions and QoL&#xD;
      vary with respect to socio-demographic variables, personality, health status and traumatic&#xD;
      events during pandemics, and to find how these relationships depend on societal factors&#xD;
      characterising municipalities in which they live. Moreover, this study will address&#xD;
      perception of pandemic consequences and associated distress in relation to personality and&#xD;
      different types of possible mediators. The prevalence rates of MH disorders will be&#xD;
      calculated as percentages of participants with a positive diagnosis. The hierarchical&#xD;
      structure of the data will be analyzed using Multilevel Random Coefficient Modeling,&#xD;
&#xD;
      CoV2Soul.RS will contribute to an international evidence base about prevalence rates of&#xD;
      psychiatric conditions during different phases of the pandemic in different regions and will&#xD;
      identify protective and harmful psychological and societal factors for MH and QoL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of MH disorders</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Prevalence of 16 most common mental health disorders assessed by M.I.N.I 7.0.2, Standard Adult version (Sheehan et al, 1998) / Seven categories of MH conditions: (1) Mood disorders (Major depressive episode, Manic episode and Hypomanic episode); (2) Psychotic disorders; (3) Anxiety disorders (panic disorder, agoraphobia, social phobia, and generalized anxiety disorder); (4) Obsessive-compulsive disorder; (5) Trauma-related disorders (Post-traumatic stress disorder); (6) Eating disorders, and (7) Substance-related and addictive disorders.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of depressive symptoms</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Depressive symptom severity will be measured by Patient Health Questionnaire - PHQ-9 (Kroenke et al., 2001); Score range 0-27 (higher scores inidicate more severe symptoms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of anxiety symptoms</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Anxiety symptom severity will be measured by General Anxiety Disorder - GAD-7 (Spitzer et al., 2006). Score range 0-21 (higher scores indicate more severe symptoms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of the pandemic-related stress</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Covid Stress Scale (Taylor et al., 2020) will be used. Score range 0-4. Higher score means worse pandemic-related psychological problems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perception of COVID-19 pandemic consequences</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Perception of the pandemic consequences on various aspects of life will be measured using 6 items, allowing for positive Covid-19 related consequences. Score range 1-5.&#xD;
Lower score means more negative perception of the pandemic consequences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life in relation to different MH conditions</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>QoL assumes focusing on satisfaction with life as a whole (to be assessed by Manchester Short Assessment of Quality of Life - MANSA (Priebe et al., 1999). Score range: 1-7. Higher score means better QoL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life in general</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Short Form survey scale - SF-12 (Ware et al., 1996) - to measure two specific QoL outcomes: 1) physical health-related quality of life (scores range: 6-20), and b) mental health-related quality of life (scores range: 6-27). Higher score means better QoL.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Mental Health Impairment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The sample will be collected via multi-stage probabilistic household sampling&#xD;
        (face-to-face, computer-assisted, or paper-pencil method). The first stage includes a&#xD;
        random sampling of municipalities as clusters, while the second stage includes a random&#xD;
        sampling of local communities in each municipality. Municipalities and local communities&#xD;
        are sampled from four regions (Capital Belgrade and suburbs, Vojvodina, West, and Southeast&#xD;
        Serbia) based on the random selection from the database created by the Serbian Institute of&#xD;
        Statistics (database includes information on the name of the settlement, municipality,&#xD;
        region, and the number of inhabitants). The third, final stage, deals with the selection of&#xD;
        the respondents using a random walk technique.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  Speaks Serbian fluently&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Cognitive impairment leading to a disability to understand questions&#xD;
&#xD;
          -  Severe neurological impairment&#xD;
&#xD;
          -  People with impaired hearing and deaf persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Goran Knezevic, Professor</last_name>
    <phone>+381113206141</phone>
    <email>gknezevi@f.bg.ac.rs</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jovana Todorovic, M.D, Assist.</last_name>
    <phone>+381112659533</phone>
    <email>jovana.todorovic@med.bg.ac.rs</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, University of Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadja P Maric, MD PhD</last_name>
      <phone>+381113307548</phone>
      <email>nadja.maric-bojovic@med.bg.ac.rs</email>
    </contact>
    <contact_backup>
      <last_name>Jovana Todorovic, MD PhD</last_name>
      <phone>+381112659533</phone>
      <email>jovana.todorovic@med.bg.ac.rs</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Faculty of Philosophy, University of Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ljiljana P Lazarevic, PhD</last_name>
      <email>ljiljana.lazarevic@f.bg.ac.rs</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty of Philosophy, University of Novi Sad</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ljiljana P Mihic, PhD</last_name>
      <email>lmihic@ff.uns.ac.rs</email>
    </contact>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <link>
    <url>http://cov2soul.rs</url>
    <description>Web-site</description>
  </link>
  <reference>
    <citation>Taylor S, Landry CA, Paluszek MM, Fergus TA, McKay D, Asmundson GJG. Development and initial validation of the COVID Stress Scales. J Anxiety Disord. 2020 May;72:102232. doi: 10.1016/j.janxdis.2020.102232. Epub 2020 May 4.</citation>
    <PMID>32408047</PMID>
  </reference>
  <reference>
    <citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.</citation>
    <PMID>11556941</PMID>
  </reference>
  <reference>
    <citation>Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7.</citation>
    <PMID>16717171</PMID>
  </reference>
  <reference>
    <citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.</citation>
    <PMID>9881538</PMID>
  </reference>
  <reference>
    <citation>Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999 Spring;45(1):7-12.</citation>
    <PMID>10443245</PMID>
  </reference>
  <reference>
    <citation>Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33.</citation>
    <PMID>8628042</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Belgrade</investigator_affiliation>
    <investigator_full_name>Nadja P Maric</investigator_full_name>
    <investigator_title>Principal Research Fellow &amp; Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Mental health disorders</keyword>
  <keyword>Stress</keyword>
  <keyword>Personality</keyword>
  <keyword>Multilevel modelling</keyword>
  <keyword>National survey</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Collected data will be completely anonymized and used in subsequent analyses at the group level. Anonymized dataset will be uploaded to a repository following all good scientific practices.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

